Trial intelligence / Profile preview

tRNS vs Dapoxetine in Lifelong Premature Ejaculation

NCT04850703Phase 2

Key facts

Status: Completed
Start: Feb 2021
Primary completion: May 2022
Countries: 1
Modality: Small Molecules

Drugs: dapoxetine
Conditions: premature ejaculation (PE)

Overview

Phase 2, randomised, double-blind trial of dapoxetine in premature ejaculation (PE) (4 arms). Primary endpoints: Wavelet Changes in Brain Biomarker at 1 month, EEG Coherence at 3 months and 1 more. Started Feb 2021; status: completed.

Design

4 arms

Study design: RandomizedDouble-blind

tRNS Arm
Active tRNS stimulation at IFG cortex.
Dapoxetine Arm
Oral dapoxetine tablet.
Placebo/Sham Arm
No active medication or stimulation.
Healthy Controls
Non-LPE participants for baseline mapping.

Who it enrols

Adult males aged 18-70 with a best-practice diagnosis of lifelong premature ejaculation for at least one year, excluding those with significant neurological or sensory impairments.

Endpoints

Primary

Wavelet Changes in Brain Biomarker1 month
EEG Coherence3 months
Adverse Events3 months

Secondary

Event-Related Potential Novelty Wave1 month

Beyond the preview

Go deeper on NCT04850703.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT04850703.